Skip to main content
. Author manuscript; available in PMC: 2013 Dec 26.
Published in final edited form as: JAMA. 2013 Jun 26;309(24):10.1001/jama.2013.6882. doi: 10.1001/jama.2013.6882

Figure 4.

Figure 4

Estimating the Use of Prostate Cancer Treatments for Men Most Likely to Benefit

Among Medicare beneficiaries diagnosed with prostate cancer, the use of advanced treatment technologies for men most likely to benefit (ie, those with high-risk disease or a low risk of noncancer mortality) increased 11%, while the use of prior standards decreased 10% over the study period (both P <.001, Pearson χ2 test).